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Abstract
Visceral adiposity is increasingly recognized as a key condition for the development of obesity related disorders, with the
ratio between visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) reported as the best correlate of
cardiometabolic risk. In this study, using a cohort of 40 obese females (age: 25–45 y, BMI: 28–40 kg/m2) under healthy
clinical conditions and monitored over a 2 weeks period we examined the relationships between different body
composition parameters, estimates of visceral adiposity and blood/urine metabolic profiles. Metabonomics and lipidomics
analysis of blood plasma and urine were employed in combination with in vivo quantitation of body composition and
abdominal fat distribution using iDXA and computerized tomography. Of the various visceral fat estimates, VAT/SAT and
VAT/total abdominal fat ratios exhibited significant associations with regio-specific body lean and fat composition. The
integration of these visceral fat estimates with metabolic profiles of blood and urine described a distinct amino acid, diacyl
and ether phospholipid phenotype in women with higher visceral fat. Metabolites important in predicting visceral fat
adiposity as assessed by Random forest analysis highlighted 7 most robust markers, including tyrosine, glutamine, PC-O
44:6, PC-O 44:4, PC-O 42:4, PC-O 40:4, and PC-O 40:3 lipid species. Unexpectedly, the visceral fat associated inflammatory
profiles were shown to be highly influenced by inter-days and between-subject variations. Nevertheless, the visceral fat
associated amino acid and lipid signature is proposed to be further validated for future patient stratification and
cardiometabolic health diagnostics.
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Introduction
Overweight and obesity pandemic has made the discovery of
their associated genome and metabolome one of the greatest
public health challenges [1,2]. Obesity, in particular visceral
adiposity, associates with inflammation and insulin resistance
which ultimately link to risks of type 2 diabetes and cardiometa-
bolic disorders. The mechanisms leading to obesity related diseases
(ORD) remain yet undefined but may involve platelet and vascular
impairments [3,4]. Moreover, visceral adiposity, also named
central adiposity or obesity, is increasingly recognized as a key
condition for the development of ORD [5–10].
The etiology and individual predisposition to visceral adiposity
remain unclear. Over the last decades, both genetic and
environmental promoters were investigated [11,12], including
genes and transcription factors associated with fat storage and
obesity [12–16], genetic inheritability [17] and gut microbiota
influence [18]. Nevertheless, similar obesogenic and diabetogenic
conditions do not necessarily lead to a universal response to
adiposity-associated cardiometabolic risks [19,20]. Indeed, indi-
viduals with normal weight (body mass index, BMI,25) can
express cardiometabolic abnormalities [19] putatively due to
differences in body composition with a key role of sub-cutaneous
versus visceral fat distribution.
From a diagnostic view, various indexes of visceral adiposity,
combining anthropometric measures were proposed, including
waist to hip ratio, (e.g. .0.9 for men and .0.85 for women) [21].
However, anthropometric-based stratification is prone to mea-
surement errors. They also show limitations when applied across
different populations (children versus adults) and ethnicities as
universal health standards cutoffs. Moreover, these tools are
insensitive to discerning the different sub-conditions of visceral
adiposity and their associated metabolic risk factors. visceral
adiposity includes indeed a complex topographical fat deposition,
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namely mesenteric and epicardial adipose tissues, and peripheric
depots around organs like stomach, liver and kidneys, which
associate with metabolic homeostatic loss [22]. The complex
visceral fat compartment exhibits, beyond its role in dietary fat
storage, signaling metabolic functions that interplay with endo-
crine and immune systems [12]. Modern imaging technologies
based on magnetic resonance (MRI) and computed tomography
(CT) can generate accurate regio-specific quantification of visceral
fat depots. Nevertheless, it is unlikely that these imaging platforms
can become universal tools for population screening and
monitoring due to cost and access limitations.
In such a context, the identification of minimally-invasive, fast
and reliable biomarkers to be used for effective and individual
therapeutic solutions for visceral adiposity management and
monitoring has become a key milestone to address the burden of
ORD with cost effective diagnostics at epidemiological level. The
development of such biomarkers may benefit from metabonomics,
which is well suited to delineate metabolic phenotype, encapsu-
lating the influence of various environment, drugs, dietary,
lifestyle, genetics, and microbiome factors [23–25]. Recent
applications have demonstrated the feasibility of associating
specific metabolite profiles to body fat distribution [26,27], and
it is envisioned that metabonomics could deliver direct or indirect
metabolic information that may generate new mechanistic
knowledge of complex physiological processes.
We sought to identify visceral adiposity specific metabolic
signature using a combination of holistic nuclear magnetic
resonance (NMR) and targeted quantitative mass spectrometry
(MS) analysis of urine and plasma from a well clinically
characterized cohort of 40 healthy obese women. Subject
characterization was based on clinical chemistry and body imaging
including visceral adipose tissue (VAT) and subcutaneous adipose
tissue (SAT) quantitation using gold standard CT completed with
whole body Dual energy X-ray Absorptiometry (DXA) [28] scans.
The VAT/SAT and VAT/total abdominal fat ratios, considered
as cardiometabolic health indicators, were calculated to probe for
metabolic-phenotype correlations [29]. In the present study, we
assess how topography of visceral adiposity links to body
composition parameters and metabolic status of healthy obese
women.
Materials and Methods
Ethics Statement
This work was approved by the Ethical Committee of Lausanne
University School Medicine (Lausanne, Switzerland). All partic-
ipants gave written informed consent in French or in English as
described in the consent procedure of the study protocol approved
by the Ethics committee. The clinical study is registered at
ClinicalTrials.gov with the identifier NCT01726647.
Participants and Experimental Design
The observational study was conducted on 40 healthy obese
Caucasian women at the out-patient obesity clinic of the
University Hospital of Lausanne (CHUV), Switzerland. The
participants had a BMI between 28 and 40, aged between 25
and 45 years old, showed no metabolic disease traits, and gave
written informed consent. Additional exclusion criteria were
diabetes, pregnancy, antibiotic therapy within 1 month prior to
the beginning of the study, any therapy (contraception apart)
within the run-in period of one week before the visit day, and
eating disorders. In the current cohort no subjects suffered from
hypertension, glucose intolerance, polycystic ovary syndrome,
thyroid dysfunction and adrenal disorders. Subjects having
recently undergone a weight loss of more than 3 kilos during
the last 3 months were also excluded. During the conduction of
the study, participants were asked to limit consumption of
special foods (spices, supplements, etc.) for one week before the
first visit day and to record their daily food intake. Fourteen
subjects out of the 40 were taking contraception, and the
subjects followed a randomized distribution across the spectrum
of visceral fat adiposity. All the subjects showed normal
menstrual cycle and took part in the study during the follicular
phase of their menstrual cycle to minimize the confounding
effects related to the hormonal changes. At a baseline (V0),
subjects underwent a standard medical visit, where overnight
fasting blood plasma samples were collected. One week later
(V1), body composition was measured using CT (at CHUV)
and iDXA (at the metabolic unit, Nestle´ Research Center,
Lausanne, Switzerland). Twenty-four-hours urine samples were
collected, resting energy expenditure was measured by indirect
calorimetry and a standard Oral Glucose Tolerance Test
(OGTT, 75 g glucose) was conducted at V1. Glucose and
insulin concentrations were measured at 215 min (t0), +30 min
(t30), +60 min (t60), +90 min (t90), +120 min (t120) after
glucose intake. One week later (V2), the subjects were asked
to consume a standardized lunch and dinner to smooth inter-
individual differences due to differences in diets. At this time
point, overnight fasting plasma and 24-hours urine samples were
collected, and fasting plasma samples again on the next day
(V3).
Anthropometric Measurements
Body weight was measured with a DetectoH scale with a
precision of 0.2 kg; height was measured with a stadiometer with a
precision of 0.5 cm. Body mass index (BMI) was calculated as
weight/height squared (kg/m2). Waist and hip circumferences
were taken respectively at the smallest standing horizontal
circumference between the ribs and the iliac crest and in a
horizontal plane around the maximum circumference of the
buttocks, using a TEC anthropometric tape (Rollfix, Hoechstmass,
Germany). The measurement was made to the nearest 0.1 cm at
normal expiration. Three measurements were taken with the
criterion that difference between the measurements had to be less
than 2 cm. Additional measurements were taken when needed
until this criterion was fulfilled.
Body Composition Assessment and Energy Expenditure
Assessments
Full body scan was performed to determine both abdominal fat
distribution and total body composition. Total body scans were
made on a GE Lunar iDXA system (software version: enCORE
version 12.10.113) with scan mode automatically determined by
the device and used the previously reported procedure [28]. For
the DXA measurement, all subjects were wearing a hospital gown
and had all metal artefacts removed. The iDXA unit was
calibrated daily using the GE Lunar calibration phantom. A
trained operator performed all scans following the operator’s
manual for patient positioning and data acquisition. During the
one-hour appointment, total body scans of each subject were
performed twice with repositioning between scans. Scans were
analyzed with the enCORE software (version 14.00.207). The
ROIs were automatically determined by the enCORE software
(Auto ROI) for total body, arms, legs, trunk, android, and gynoid
regions. An experienced DXA operator also verified and, when
indicated, repositioned the ROI placements (Expert ROI). In
addition to iDXA scan, waist and hip measurements were
performed.
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The CT scan measures of the abdominal region, for the
quantification of intra-peritoneal and sub-cutaneous fat, were
performed on 64 multi-detector CT scanner (VCT Lightspeed,
GE Medical Systems, Milwaukee, USA). Subjects lied in the
supine position with their arms above their head and legs elevated
with a cushion. A single scan (10 mm) of the abdomen is acquired
at the level of L4–L5 vertebrae and analyzed for a cross-sectional
area of adipose tissue, expressed in square centimeters. The
following acquisition parameters were used: 120 Kv, 100–200 mA
with z-axis dose modulation and a field of view 500 mm. Axial
transverse images of 5 mm slice thickness are reconstructed using a
standard kernel. The quantification process uses a semi interactive
commercially available algorithm for segmentation of subcutane-
ous and intra-abdominal fat on the Advantage Window worksta-
tion (GE Medical Systems). Resting metabolic rate was measured
by using open-circuit indirect calorimetry, with a Deltatrak II
(Datex Instruments).
Blood Pressure and Clinical Chemistry
Blood pressure was measured in the lying position using a
digital pressure monitor (HEM-907, Omron). Mean arterial
blood pressure (MAP) was also calculated from systolic (SYS)
and diastolic (DIA) arterial blood pressure: MAP = 1/3 SYS +2/
3 DIA). Blood samples were collected in the morning after an
overnight fast. Glucose (Ecoline 100 Merck, KgaA, Darmstadt,
Germany), total cholesterol (Roche CHOD-PAP, Roche Mo-
lecular Biochemicals Systems, GmbH, Mannheim, Germany),
high-density lipoprotein cholesterol (HDL-C plus, second
generation, Roche Diagnostic GmbH, Mannheim, Germany)
and triglycerides (TG GPO-PAP, Roche Diagnostic) were
measured using an automatic Hitachi 917 Roche apparatus.
Low-density lipoprotein cholesterol was then calculated by the
Friedwald’s formula. Plasma insulin was assayed by specific
radioimmunoassay (Aldatis Insulin, code 10624, Casalecchio di
Reno, BO, Italy). Urea, creatinine, sodium and potassium
concentrations, ALAT, ASAT, cGT, were measured by SSCC
(Socie´te´ Suisse de Chimie Clinique) 37uC method with kit
Roche and kit BioMe´rieux with automatic Hitachi 917 Roche,
according to routine analytic methods. Intra-assay precision
error (CV) for these measurements was 1.0–3.1%. All
biochemical analyses were carried out by certified laboratories
(ISO/CEI 17025); they were run in duplicate or triplicate
samples, after having been previously tested in a healthy
population. Insulin resistance status was assessed as homeostasis
model assessment of insulin resistance (HOMA-IR): insulin (mU/
mL)6glucose (mmol/L)/22.5. Finally, free fatty acids were
analyzed by WAKO NEFA-HR (300 mL plasma, EDTA) using
Siemens XPAND DIMENSION (WA2 434–91795, WA2 436–
91995, USA).
Metabonomics Analysis
Targeted LC-MS/MS metabonomic approach using the
Biocrates Life Sciences AbsoluteIDQTM kit was applied to plasma
samples as previously published [30]. Briefly, well plate prepara-
tion and sample application and extraction were carried out
according to the manufacturer’s instructions. A final volume of
10 ml of plasma was loaded onto the provided 96-well plate. Liquid
chromatography was realized on a Dionex Ultimate 3000 ultra
high pressure liquid chromatography (UHPLC) system (Dionex
AG, Olten, Switzerland) coupled to a 3200 Q TRAP mass
spectrometer (AB Sciex; Foster City, CA, USA) fitted with a
TurboV ion source operating in electrospray ionization (ESI)
mode. Sample extracts (20 ml) were injected twice (in positive and
negative ESI modes) via direct infusion using a gradient flow rate
of 0–2.4 min: 30 ml/min, 2.4–2.8 min: 200 ml/min, 2.9–3 min:
30 ml/min. MS source parameters were set at: desolvation
temperature (TEM): 200uC, high voltage: 24500 V (ESI 2),
5500 V (ESI +), curtain (CUR) and nebuliser (GS1 and GS2)
gases: nitrogen; 20, 40, and 50 psi; respectively, nitrogen collision
gas pressure: 5 mTorr. MS/MS acquisition was realised in
scheduled reaction monitoring (SRM) mode with optimised
declustering potential values for the 163 metabolites screened in
the assay. Raw data files (Analyst software, version 1.5.1; AB
Sciex, Foster City, CA, USA) were imported into the provided
analysis software MetIQ to calculate metabolite concentrations.
List of all detectable metabolites is available from Biocrates Life
Sciences, Austria (http://biocrates.com). See Text S1 for more
details. Samples were also subjected to analysis for inflammation
markers quantification by UPLC-ESI-MS/MS using isotope
dilution technique. See Text S2 for more details.
Heparinized blood plasma samples (400 mL) were introduced
into 5 mm NMR tubes with 200 mL of deuterated phosphate
buffer solution (KH2PO4 with a final concentration of 0.2 M).
Deuterium was employed as locking substance. Twenty-four-hours
urine samples (400 mL) were introduced into 5 mm NMR tubes
with 200 mL of deuterated phosphate buffer solution (KH2PO4
with a final concentration of 0.2 M, and containing 1 mM of
sodium 3-(trimethylsilyl)-[2,2,3,3-2H4]-1-propionate (TSP). Meta-
bolic profiles were measured on a Bruker Avance III 600 MHz
spectrometer equipped with an inverse 5 mm cryogenic probe at
300 K (Bruker Biospin, Rheinstetten, Germany). See Text S3 for
more details.
Chemometrics
Due to the non-normal distribution of the visceral adiposity, the
following parameters were employed for the subsequent metabo-
nomics analysis: log-transform value of the visceral fat content, of
the intraperitoneal/subcutaneous fat ratio (ratio 1), or of the
intraperitoneal/abdominal fat ratio (ratio 2). The plasma and
urine NMR spectra were converted into 22 K data points over the
range of d 0.2–10.0 ppm using an in-house developed MATLAB
routine excluding the water residue signal between d4.68–
5.10 ppm. Chemical shift intensities were normalized to the sum
of all intensities within the specified range prior to chemometric
analysis for urine and plasma samples. In addition, 24-hours urine
spectral data were also normalized to creatinine values quantified
in parallel using an adapted Jaffe method.
Chemometric analysis was performed using the software
package SIMCA-P+ (version 12.0, Umetrics AB, Umea˚, Sweden)
and in-house developed MATLAB (The MathWorks Inc., Natick,
MA, USA) routines. In order to detect the presence of similarities
between metabolic profiles, Principal Component Analysis (PCA)
[31], Projection to Latent Structure (PLS) [32], and the
Orthogonal Projection to Latent Structures (O-PLS) [33] were
used. Analyses were conducted to investigate relationships between
body composition, OGTT response and metabolic profiles. Seven-
fold cross validation was used to assess the validity of the model
[34]. The classification accuracy of the O-PLS-DA model was
established from the predicted samples in the 7-fold cross-
validation cycle. The modeling was also tested for assessing
inter-days metabolic variations, by considering each visit sepa-
rately.
In addition, targeted MS data were analyzed by Random
Forests (RFTM) using the package ‘randomForest’ [35]. In
particular, the selection of the most robust markers required
additional multivariate data analyses using RFTM (with 500 trees,
and a random variable sampling at tree split of 5) and the
implemented variable importance features in RFTM (mean
Metabolic Signatures of Visceral Adiposity
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decreases in accuracy/node impurity) to determine variables that
discriminates better subjects according to their visceral fat status
(Q1 versus Q4) as assessed using either value of the intraperitoneal
fat volume, ratio 1 and ratio 2.
Spearman autocorrelation matrices were calculated using R and
corresponding graphs were produced using the package Rgraphviz
v.1.32.0. Univariate significance tests for confirmation were also
performed in R.
Results
Clinical Characteristics of the Obese Cohort
Anthropometric and clinical parameters of the cohort were
measured at visit 2 (V2) and main parameters are shown as per
stratification in four quartiles (Q1–4, n = 10) based on the log10
value of the intraperitoneal fat volume measured using CT (Table
S1), log10 value of intraperitoneal/subcutaneous fat ratio (ratio 1,
Table S2), or log10 value of intraperitoneal/abdominal fat ratio
(ratio 2, Table 1).
Relationships between Visceral Fat Indicators and other
Body Composition Parameters
PCA and a heat map based on the Spearman correlations on
CT scan and DXA data were used to assess the relationships
across the CT and DEXA generated body composition param-
eters (Figure 1, Figure S1). In particular, relationships with the
different indicators of visceral adiposity including IPVF, log10
values of IPVF, ratio 1 and ratio 2, android/gynoid fat ratio were
included. The analysis therefore described how visceral adiposity
relates to region-specific lean, fat and bone distribution across the
40 human subjects according to the type of VAT indicator.
Statistically significant correlations (95% confidence interval) are
shown in Figure 1. The specific relationships between Log10 ratio
1 and the other parameters were further assessed using a
multivariate OPLS model (Figure S2).
Relationships between Visceral Fat Indicators and Clinical
Parameters
PCA and a heat map based on the Spearman correlations
between body composition and main clinical parameters of the 40
human subjects were also employed to probe for relationships with
key physiological endpoints (Figure 2, Figure S3). The specific
Table 1. Descriptive statistics of subjects stratified according to intraperitoneal/abdominal fat ratio.
Factor Q1 Q2 Q3 Q4 Mann-Whitney p value (Q1/Q4)
Log10 Ratio2 20.7±0.05 20.61±0.02 20.52±0.02 20.40±0.06 ,0.0001
IPVF, mL 3065.1±695.5 4223±837.6 5111.2±1036.3 5407±1564.6 0.0002
HOMA-IR 4.24±2.02 4.95±1.49 6.06±1.87 6.12±1.23 0.011
Insulin, (mU/mL) 18.6±9.21 22.12±6.32 24.36±7.22 25.44±4.62 0.014
Glucose, mmol/L 4.9560.35 5.1760.52 5.4160.49 5.3760.5 0.057
TG, mmol/L 1.0460.43 2.2562.1 1.2860.45 1.5260.57 0.093
ALAT/ASAT ratio 0.8660.25 0.9160.21 0.9960.3 1.0860.34 0.120
Age, years 33.964.89 32.863.58 3864.42 37.665.82 0.138
ALAT, U/L 18.466.11 19.265.07 23.568.34 27.1613.28 0.139
HDL, mmol/L 1.5460.43 1.3260.29 1.3860.25 1.3260.24 0.181
GGT, U/L 20611.86 17.566.88 21.164.84 25.44611.26 0.191
Creatinine, mmol/L 65.669.45 65.2611.2 64.7869.28 70.366.53 0.256
HDL/Chol ratio 3.7761.07 4.4261.22 3.9960.97 4.2460.95 0.289
Na, mmol/L 140.461.35 140.861.32 141.561.58 139.961.1 0.328
Waist/Hip ratio 0.860.07 0.8160.06 0.8560.07 0.8460.09 0.351
Urates, mmol/L 275.2641.93 263.22671.45 303.4675.28 285631.7 0.352
Calorimetry, kcal/24 h 13576191.78 14346142.61 14696152.49 14336210.82 0.363
ASAT, U/L 21.463.24 21.464.48 2466.94 24.566.7 0.401
Waist, cm 97.2868.28 103.3968.7 108.72611.71 104.73613.84 0.458
Hip, cm 12265.47 12867.48 127.3466.29 122.2869.65 0.564
NEFAs, mmol/L 544.56201.51 580.66301.38 596.26185.79 585.16188.62 0.664
K, mmol/L 4.0560.18 4.160.18 3.9960.25 4.0460.18 0.876
MAP, mmHg 57.8618.6 71.1619.75 62.4620.97 57.8614.15 0.879
Cholesterol, mmol/L 5.5261.01 5.5860.85 5.3160.68 5.4860.97 0.909
BMI, kg/m2 34.0163.27 36.3463.62 3762.95 34.5964.42 0.939
LDL, mmol/L 3.560.97 3.5660.88 3.3460.61 3.4760.79 1
Key: Qi: data for population quartile i according to intraperitoneal/abdominal fat ratio. BMI = body mass index, HDL-C = high density lipoprotein cholesterol,
homeostasis model assessment of insulin resistance = HOMA-IR, LDL-C = low density lipoprotein cholesterol, TG = triglycerides, MAP = mean arterial blood pressure,
ALAT = alanine aminotransferase, ASAT = aspartate aminotransferase, GGT = gamma-glutamyl transpeptidase, NEFAs = non esterified fatty acids. Data are reported as
mean values 6 SD.
doi:10.1371/journal.pone.0073445.t001
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relationships between Log10 ratio 1 and the other parameters were
further assessed using a OPLS multivariate model (Figure S4).
Visceral Adiposity Links to Different Metabolic Response
to Oral Glucose Tolerance Test
Overall glucose and insulin response to OGTT correlated
significantly with visceral adiposity as observed by linear regression
with OGTT glucose and insulin AUC (Figure S5). When
comparing subjects stratified according to VAT content defined
quartiles, glucose-induced insulin secretion gradually increased
between Q1 and Q4. However, significant blood glucose
variations were only observed within the first 60 minutes post-
glucose absorption across the VAT quartiles (Table 2, similar
response was observed for different Log10 ratios).
Plasma Metabolic Profiles Revealed a Lipid and Amino
Acid Signature Associated with Visceral Adiposity
In order to identify phenotypic signatures of visceral fat
deposition, plasma samples were analysed using 1H-NMR and
targeted LC-MS/MS metabonomic approach. Analyses were
conducted on the fasting plasma samples collected at V0 and V2.
OPLS analysis of 1H-NMR samples collected at V0 and V2
Figure 1. Statistically significant Spearman correlation map between CT scan and DXA body composition parameters (95%
confidence interval). IPVF and Log10 IPVF correlated similarly to fat body composition parameters. Log10 IPVF showed a strong association with
android/gynoid fat ratio (r = 0.48, p = 0.0015), Log10 VAT/SAT (r = 0.72, p,0.001) and Log10 VAT/total abdominal fat (r = 0.71, p,0.001), subcutaneous
fat (r = 0.58, p,0.001), and some dependencies with lean mass parameters. Log10 values of VAT/SAT and VAT/total abdominal fat ratios were poorly
correlated with most body composition parameters, except for arms lean mass (r = 0.43, p = 0.0056; r = 0.42, p = 0.0070), whilst VAT/SAT correlated
with subcutaneous fat (r = 0.58, p = 0.0489), and android/gynoid fat ratio (r = 0.48, p = 0.0453). NB: Blue denotes negative correlation, orange denotes
positive correlation, and black denotes no correlation.
doi:10.1371/journal.pone.0073445.g001
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showed some subtle but significant associations between blood
plasma lipids and visceral fat deposition (R2X: 0.68; R2Y: 0.506;
Q2Y: 0.167), further confirmed by random forest analysis (Figure
S6). These results suggested plasma lipid remodelling marked by
changes in glycerophospholipids and fatty acid saturation patterns.
Targeted MS metabonomics provided quantitative measures of
163 metabolites, including amino acids, sugars, acyl-carnitines,
sphingolipids, and glycerophospholipids in plasma samples. A
metabolic signature of visceral fat adiposity was determined using
an OPLS analysis across the 40 individual subjects (R2X: 0.29;
R2Y: 0.68; Q2Y: 0.32). The model was then tested for assessing
inter-days metabolic variations, by considering each visit sepa-
rately and by modelling potential inter-days metabolic differences
(data not shown). No statistically significant differences were
observed in the blood plasma metabolic profile between V0 and
V2 (data not shown). Furthermore, the most robust metabolic
signatures of visceral fat status using either value of the
intraperitoneal fat volume, ratio 1 and ratio 2, were selected by
Random Forests analysis. Using this methodology, metabolite
importance and robustness in predicting visceral fat adiposity were
assessed using metabolic data collected at V0 and V2 (Figure 3). A
signature of specific amino acids, diacyl phospholipids and ether
lipid species was identified and shown to be preserved significantly
between days (Figure 3). Ultimately, 26 metabolites were retained
Figure 2. Statistically significant Spearman correlation map between body fat composition parameters and clinical measures (95%
confidence interval). Log10 values of IPVF, VAT/SAT, VAT/total abdominal fat were strongly associated with HOMA-IR (r = 0.39, p = 0.015; r = 0.56,
p,0.001; r = 0.55, p,0.001) and fasting insulin (r = 0.35, p = 0.0275; r = 0.49, p = 0.0017; r = 0.48, p = 0.0020). Strong associations were observed with
ALAT (r = 0.39, p = 0.0128; r = 0.37, p = 0.0175; r = 0.38, p = 0.0167) and ALAT/ASAT ratio (r = 0.44, p = 0.0044; r = 0.35, p = 0.0268; r = 0.35, p = 0.0302).
IPVF and Log10 values of IPVF correlated with waist (r = 0.55, p,0.001; r = 0.35, p = 0.04) and waist/hip ratio (r = 0.69, p,0.001; r = 0.52, p = 0.0017), but
not Log10 values of VAT/SAT and VAT/total abdominal fat. NB: Blue denotes negative correlation, orange denotes positive correlation, and black
denotes no correlation.
doi:10.1371/journal.pone.0073445.g002
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(Figure 3, Table 3, Table S3 and Table S4). Metabolite
importance and robustness in predicting visceral fat adiposity as
assessed by Random forest analysis using metabolic data collected
at V0 and V2, highlighted 7 most robust markers, including
tyrosine, glutamine, PC-O 44:6, PC-O 44:4, PC-O 42:4, PC-O
40:4, and PC-O 40:3.
To assess potential overlaps with insulin resistance, the
predictive performance of the seven most promising markers was
evaluated using two linear discriminant classification models based
on both visceral fat and HOMA-IR stratification of the
population. Model on visceral fat showed a sensitivity and
specificity in cross-validation of 0.90, which was fairly different
from the model on HOMA-IR (sensitivity (CV): 0.95, specificity
(CV): 0.68). This loss of specificity for the HOMA-IR model was
interpreted as a stronger association of the selected markers with
visceral adiposity. Figure 4 displays metabolite variations in the
study population stratified in four quartiles according to visceral
fat adiposity (Log10 value of intraperitoneal fat).
Eicosanoid Profiling Suggests that the Relationship
between Visceral Adiposity, Inflammation and Oxidative
Stress is Affected by other Environmental Confounders
To investigate relationships between visceral fat deposition and
low-grade inflammatory status, a targeted LC-MS/MS method
was employed to measure plasma eicosanoid concentrations at V0
and V2. Here, Random Forests analysis on quantitative data
displayed statistical relevant changes associated with the visceral
adiposity (Table 3, Figure S7, Table S3 and Table S4).
Urine Metabolic Profiles Suggested a Different Energy
and Microbial Metabolism in Subjects with High Visceral
Adiposity
1H-NMR spectra of the 24 hours urine samples were
normalized to creatinine concentration and were analyzed using
supervised chemometric analysis to assess the occurrence of
relationships with visceral adiposity. PLS analyses using 2
predictive components showed relationships between urine met-
abolic profile and visceral adiposity, at both timepoints, V1 or V2
(respective Q2Y values being 0.05, 0.217 and 0.54). OPLS analysis
confirmed a statistically significant relationship at V2 (1 predictive
and 2 orthogonal components, Q2Y value of 0.27). Visceral
adiposity was correlated with changes in central energy metabo-
lism (increased urinary excretion of 3-methyl-2-oxovaleric acid
(direct catabolic product of isoleucine), N1-methyl-2-pyridone-5-
carboxamide (2PY), N1-methyl-4-pyridone-3-carboxamide (4PY),
fucose, pyruvate, ethanolamine and lactate), protein metabolism
(increased pseudouridine, decreased taurine, and 3-methyl-histi-
dine), and gut microbial activities (decreased 4-cresol sulfate).
Since the subjects received a controlled dietary intake during V2,
these results suggest a strong incident of visceral fat adiposity on
individual nutritional response as noted here.
Integration of Visceral Adiposity, Clinical Parameters and
Metabonomics Markers
A heat map based on the Spearman correlations on CT scan,
main clinical parameters and selected discriminant metabolites
measured in plasma and urine of the 40 human subjects was used
to assess the relationships between the urine and plasma
metabonomics readouts and key physiological endpoints. These
correlations are shown in Figure 5 and Figure S8. Such an
approach enabled the assessment of linear relationships between
the parameters across the 40 subjects. In addition, for the 26 most
influential metabolites, the VIP values generated from PLS
regression against the visceral fat estimates are reported in Table
S5, to further exemplify these relationships. In particular, we
investigated the statistical relationships between selected metabo-
lites, HOMA-IR, ALAT/ASAT ratio and visceral adiposity
(Figure 5). The spearman correlation network between blood
Table 2. Insulin and glucose response to oral glucose tolerance test according to intraperitoneal/abdominal fat ratio.
Time variations Delta t30–t0 Delta t60–t0 Delta t90–t0 Delta t120–t0
Insulin concentrations (mU/mL)
Q1 74.69631.76 85.94649.76 75.25641.38 38.93632.32
Q2 77.93633.43 97.04641.48 62.87634.48 54.27631.97
Q3 79.25652.36 68.07642.78 91.01655.36 66.61632.39
Q4 108.80649.86 114.764664.45 108.73649.17 70.92629.56
t-test p values (Q1 vs. Q4) 0.085 0.278 0.117 0.033
Glucose concentrations (mmol/L)
Q1 1.6360.71 1.3061.01 0.7460.0.86 0.0161.86
Q2 2.4860.60 2.2961.39 1.6863.47 1.8863.72
Q3 3.0361.42 2.8161.59 1.7961.60 1.1661.28
Q4 3.2160.93 3.3361.6 1.9562.00 1.0962.05
t-test p values (Q1 vs. Q4) 0.0005 0.0006 0.096 0.2355
Estimates of beta cell function and insulin sensitivity OGTT Delta(Ins t30–t0)/(Gly t30–t0)
Q1 52.09626.56
Q2 31.16612.20
Q3 39.42632.53
Q4 41.81640.61
t-test p values (Q1 vs. Q4) 0.511
NB: Values are reported as mean values 6 SD. Key: Qi: data for population quartile i according to intraperitoneal/abdominal fat ratio.
doi:10.1371/journal.pone.0073445.t002
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plasma metabolites showed a strong connection between the
remodelling of ether lipid species and specific diacyl phospholipids,
which seem quite independent of changes in eicosanoids and
amino acids.
Discussion
Over the last decades, there was increasing awareness that
prevalence of fat storage in the trunk/android compartment over
gynoid (i.e. mainly subcutaneous) region associates with increased
insulin resistance and related cardiometabolic risk [36,37].
Assessments of visceral adiposity using VAT/SAT (ratio 1) and
VAT/total abdominal fat (ratio 2) ratios were conducted in the
present study, as they are known to better correlate to
cardiometabolic health, outperforming associative power of single
BMI and VAT [29]. In our cohort, IPVF, Log10 IPVF and waist/
hip ratio correlated similarly to several fat body composition
parameters (total, trunk, arms, android and abdominal fat),
concurring with literature [26,36,37]. VAT/SAT and VAT/total
abdominal fat ratios were independent of these variables, and also
related to android/gynoid fat ratio. Visceral adiposity expressed by
log10 values of IPVF, ratios 1 and 2 associated significantly with
insulin (fasting insulin, HOMA-IR) and hepatic (ALAT/ASAT)
metabolism unlike with other clinical parameters, including HDL,
LDL, and TG, which is consistent with the healthy status of the
enrolled subjects.
Ether Lipid Metabolic Signature of Visceral Adiposity
Highlights Potential Deregulations in Lipoprotein and
Phospholipid Metabolic Pathways
A visceral fat signature of specific amino acids and ether
phosphocholine lipid species was shown to be preserved signifi-
cantly between days (Figure 3). Ether lipid species represent 18%
of the total pool of phospholipids and are mainly composed by
plasmalogens. Although little is known about their systemic
metabolism, plasmalogens have been implicated in protection of
cellular functions against oxidative damage [38], and their
Figure 3. Plot describing metabolite importance and robustness in predicting visceral fat adiposity as assessed by Random forest
analysis using metabolic data collected at V0 and V2.Visceral adiposity was associated with increasing concentrations of amino acids
(glutamine, leucine/isoleucine, phenylalanine and tyrosine), lysophosphatidylcholine LPC 24:0 and diacyl phospholipids (PC 30:0, PC 34:4). In addition,
visceral adiposity was marked by a depletion in ether lipid species PC-O 36:3, PC-O 40:3, PC-O 40:4, PC-O 40:6, PC-O 42:2, PC-O 42:3, PC-O 42:4, PC-O
44:3, PC-O 44:4, PC-O 44:6, and two diacyl phosphocholines (PC 42:0 and PC 42:2). To reflect the weight of the selected biomarkers in the classification
of visceral adiposity, a pooled mean decrease of accuracy for each compound was calculated from 10000 forest generations. Higher variable
importance corresponds to higher values of pooled mean decrease in accuracy. Key: IPVF, intraperitoneal fat volume; LPC, Lysophosphatidylcholines;
PC, Phosphatidylcholines; PC-O, 1-O-alkyl-2- acylglycerophosphocholines; Ratio1, intraperitoneal/subcutaneous fat ratio; Ratio 2, intraperitoneal/
abdominal fat ratio. Assignment of PC-O species is made on the assumption that only even numbered carbon chains are present. A potential overlap
between PC species containing odd-chain fatty acids and even-chained PC-O species cannot be excluded with low mass resolution.
doi:10.1371/journal.pone.0073445.g003
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diminished levels have been reported in several diseases [39], e.g.
diabetes mellitus, vascular diseases and obesity [40] or peroxisome
biogenesis defects [41], all these conditions exhibiting a common
feature as regards with oxidative stress. Furthermore, our work
supports the association of polyunsaturated phospholipids species
with visceral adiposity [40]. Using a correlation analysis, PC-O
species reduced with increased visceral fat adiposity and positively
correlated to HDL circulating levels, a feature previously reported
for ageing-associated cardiometabolic disorders [42] and lipopro-
tein associated with visceral adiposity [26,43,44]. Indeed, lipopro-
tein fractions (VLDL, LDL, and HDL) were previously charac-
terized by a specific ether lipid class and species pattern [39]. Our
results confirm the involvement of PC-O species in glucose
metabolism providing an additional pattern of PC-O species
(PC-O 40:3, PC-O 40:4, PC-O 42:4, PC-O 44:3, and PC-O 44:6)
newly associated with visceral adiposity. Further correlation
analysis showed significant association between HOMA-IR and
circulating levels of PC-O 44:4, PC-O 44:5, PC-O 44:6 and PC-O
42:4. Floegel et al. reported a pattern of PC-O species (PC-O 34:3,
PC-O 40:6, PC-O 42:5, PC-O 44:4, and PC-O 44:5) correlated with
risk of T2D [45]. Taken together with literature data, our results
suggest the occurrence of a subset of PC-O species (PC-O 40:3, PC-
O 40:4, and PC-O 44:3) that would be specific to visceral adiposity.
Additionally, we observe that PC-O 42:4, PC-O 44:4, PC-O 44:5
and PC-O 44:6 appear as constant feature of insulin resistance
status or Type 2 pre-diabetic state.
Table 3. Metabolite variations across subjects stratified according to intraperitoneal/abdominal fat ratio.
Metabolites (concentration) Q1 Q2 Q3 Q4
Mann-
Whitney p
value (Q1/Q4)
PC-O 42:4*, mmol/L 1.3460.33 1.0960.28 1.0960.37 0.8260.22 0.00298
PC-O 40:3*, mmol/L 1.4160.27 1.4660.38 1.2760.3 0.8660.42 0.00421
PC-O 44:6*, mmol/L 1.5260.56 1.2260.3 1.1160.5 1.0360.32 0.01013
PC-O 44:4*, mmol/L 0.860.3 0.6760.24 0.6360.19 0.5160.18 0.01721
PC-O 40:4*, mmol/L 2.7960.56 2.960.73 2.4760.69 2.0260.83 0.01784
Glutamine, mmol/L 615.566107.95 7486193.49 792.16260.61 714694.03 0.02468
PC-O 36:3*, mmol/L 7.0461.68 6.762.61 7.1161.82 5.561.24 0.02792
8-iso-PGF2a, ng/100 mL 0.00860.011 0.00460.001 0.00360.002 0.00360.001 0.0370
Phenylalanine, mmol/L 49.9614.16 50.4768.45 62.82622.17 56.4268.38 0.04113
PC-O 44:5*, mmol/L 2.2960.74 2.0360.55 1.960.74 1.7160.7 0.04113
Leucine+Isoleucine, mmol/L 181.44653.02 214.2656.71 202.4627.39 228.8633.83 0.04536
Tyrosine, mmol/L 61.97611.02 80.54622.21 75.91621.83 80.99624.69 0.05347
PC-O 42:2*, mmol/L 0.6660.23 0.5660.14 0.5360.16 0.4560.18 0.05347
PC-O 40:6*, mmol/L 3.8160.86 3.2761.09 2.860.84 2.7461.09 0.06525
PC-O 42:3*, mmol/L 0.8960.2 0.9260.14 0.960.27 0.6360.26 0.06525
PC-O 36:2*, mmol/L 11.2962.64 11.8662.68 10.3863.08 9.1762.09 0.07865
PC 42:0, mmol/L 0.6560.23 0.4860.16 0.4760.08 0.4860.14 0.07889
Palmitoylcarnitine, mmol/L 0.0760.02 0.0760.03 0.0760.03 0.1060.04 0.12065
PC 30:0, mmol/L 4.4361.48 5.1762.35 5.7561.98 5.5761.76 0.1564
PC-O 44:3*, mmol/L 0.2160.06 0.260.04 0.1560.06 0.1760.05 0.1564
PC-O 34:1*, mmol/L 9.9462.22 9.7863.84 8.4862.15 8.5360.99 0.17752
15-HETE, ng/100 mL 0.0860.05 0.1760.29 0.160.13 0.160.18 0.18231
PC-O 34:2*, mmol/L 10.6663.5 9.3163.51 9.3864.57 8.7761.76 0.21102
LPC 24:0, mmol/L 0.3660.25 0.5160.24 0.5260.36 0.4660.31 0.21613
Octenoylcarnitine, mmol/L 0.0460.02 0.0560.02 0.0560.04 0.0560.02 0.25258
9-HODE, ng/100 mL 0.1060.02 0.1260.05 0.1160.02 0.1260.04 0.25831
PC 34:4, mmol/L 1.360.46 1.5361.14 1.4160.52 1.5560.75 0.31537
Caproylcarnitine, mmol/L 0.2260.10 0.260.09 0.1460.06 0.3060.19 0.40018
PC 42:2, mmol/L 0.260.06 0.1960.11 0.1360.05 0.1760.08 0.40018
12-HETE, ng/100 mL 0.6060.72 0.2860.3 1.1562.15 0.4160.36 0.8421
AA, ng/100 mL 784.226236.64 764.96314.46 854.76193.24 785.66160.86 0.96823
NB: Blood plasma metabolites highlighted by multivariate analyses are reported as mean values 6 SD. Key: Qi: data for population quartile i according to
intraperitoneal/abdominal fat ratio. 12-HETE, 12-hydroxy-eicosatetraenoic acid; 15-HETE, 12-hydroxy-eicosatetraenoic acid; 9-HODE, 9-Hydroxy-10,12-octadecadienoic
acid; AA, arachidonic acid; LPC, Lysophosphatidylcholines; PC, Phosphatidylcholines; PC-O, 1-O-alkyl-2- acylglycerophosphocholines; SM, Sphingomyelines; SM-OH,
Hydroxy-Sphingomyelin.
*Assignment of PC-O species is made on the assumption that only even numbered carbon chains are present. A potential overlap between PC species containing odd-
chain fatty acids and even-chained PC-O species cannot be excluded with low mass resolution.
doi:10.1371/journal.pone.0073445.t003
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Our results further supported by the recent study by Szymanska
et al. [26], strongly suggest a remodelling of phospholipid species,
which may result from a multi-factorial origin, including dietary
factors, gut functional ecology, intestinal absorption, as well as
Platelet-Activating Factor (PAF) metabolic pathways and phos-
pholipase A2 activities [46,47], which are modulated by obesity
and insulin resistance [3,48].
Evidence tends to support the notion that oxidative-stress-
induced dysregulation of inflammation and adipokines may
mediate the obesity-related metabolic derangement [49]. Here,
high visceral fat subjects tend to display a different balanced
network of lipid mediators, as noted by an alteration of the
arachidonic metabolism. However, the greater inter-day variabil-
ity in the dynamics of these pathways may suggest that the visceral-
Figure 4. Bar plots describing metabolite variations in the study population stratified in four quartiles according to visceral fat
adiposity (intraperitoneal fat) at V2. Statistical significance is reported in Table S3. Key: PC-O, 1-O-alkyl-2- acylglycerophosphocholines.
Assignment of PC-O species is made on the assumption that only even numbered carbon chains are present. A potential overlap between PC species
containing odd-chain fatty acids and even-chained PC-O species cannot be excluded with low mass resolution.
doi:10.1371/journal.pone.0073445.g004
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associated influence is also dependent on lifestyle and dietary
intakes. Previously reported studies displayed how enhanced lipid
peroxidation and persistent platelet activation associate to visceral
adiposity might be influenced by weight-loss program or simply by
the type of fat in meals [3,50]. Here, a decreased circulating level
of 8-iso-PGF2a was highlighted, a feature negatively correlated
with the visceral fat ratio and android fat across the 40 subjects
and positively with blood pressure. Others have characterized how
increased blood and urinary levels of 8-iso-PGF2a correlate with
oxidative stress and android obesity [3,51]. 8-iso-PGF2a is
generally released from the site of inflammation as esters of
phospholipid (bound) or through the action of phospholipase A2 in
free form [52]. 8-iso-PGF2a concentration was positively corre-
lated with the concentrations of several ether lipids decreasing with
visceral adiposity (e.g. PC-O 40:4, PC-O 42:2, PC-O 42:3, PC-O
42:4). Furthermore, whilst 12- and 15-LO enzymes are known to
be up-regulated in visceral adipocytes, their products (12- and 15-
hydroxy-eicosatetraenoic acid 12/15-HETE) promote proinflam-
matory state and impairing insulin signaling in adipocytes [4,53].
However, the circulating levels of 12/15-HETE concentrations
were not statistically different between groups, suggesting that the
circulating levels of these molecules in fasting blood are not
directly related to visceral fat metabolism under the current
experimental conditions.
Visceral Adiposity Links to a Specific Amino Acid Pattern
Associated with Deregulated Insulin Signaling
Plasma amino acids (including glutamine, leucine/isoleucine,
phenylalanine and tyrosine) significantly contributed to the
metabolic phenotypes of visceral adiposity, with a greater
specificity being observed for glutamine and tyrosine levels. Our
findings are partly supported by a recent report on obese Japanese
subjects in which plasma levels of alanine, glycine, glutamate,
tryptophan, tyrosine and BCAA amino acids associated with
visceral fat accumulation [27]. Our results support associations of
levels of BCAA and tyrosine with visceral adiposity, irrespective of
ethnicity, lifestyle and environmental conditions. Although
requiring proper validation on a larger population, one may
postulate that levels of glycine, glutamate, tryptophan, glutamine
and phenylalanine associated with visceral adiposity could be
genetic and environmental dependent either in healthy obese [27]
or in pre-diabetic subjects as recently reported [54]. Association of
BCAA levels with visceral adiposity is supported by previous
reports proposing these as co-variants of insulin resistance [55,56].
In fact, BCAA catabolism is tightly intertwined with insulin
resistance, and greater circulating levels of BCAA were reported
under these conditions [57,58]. In particular, a combination of
three amino acids (isoleucine, phenylalanine, tyrosine) could
predict future diabetes (.5-fold higher risk for individuals in top
quartile) [59,60]. Recent results showed that fat tissue metabolism
is key in determining the blood level of branch chain amino acids
[61]. Indeed, it is suggested that altered signaling in white adipose
tissue under insulin resistance, pre-diabetes or type 2 diabetes
Figure 5. Spearman correlation network between blood plasma metabolic markers highlighting strong functional relationships
between phospholipids and eicosanoid metabolic remodelling. Non significant correlations and those between 0.4 and 20.4 were removed
to reduce the number of edges and facilitate visualization.
doi:10.1371/journal.pone.0073445.g005
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conditions can induce decreased expression of branched-chain-
keto acid dehydrogenase (BCKD) with inferred impairment of
BCAA utilization as metabolic fuel in this tissue. As a result, one
may postulate that this reduced BCAA utilization in adipose tissue
increases the circulating pool of isoleucine and its direct catabolic
product, the 3-methyl-2-oxovaleric acid, via reversible transami-
nation by branched chain amino-acid transaminase 1. This may
explain the observed increased urinary excretion of 3-methyl-2-
oxovaleric acid in high visceral fat subjects.
In the present study, visceral adiposity was associated with
different response to OGTT, as noted with an early increase in
post-glucose insulin concentrations and enhanced glucose-induced
insulin secretion. Knowing that insulin resistance is a causal
mechanism in the etiology of visceral fat development and related
disorders, the observation of such amino acid and OGTT patterns
support this functional relationship. Moreover, removal of
intraperitoneal fat tissue, a major compartment of visceral
adiposity, significantly restores glucose and insulin towards normal
levels in humans, but not subcutaneous adipose tissue [22].
The study presents several potentialities, including the use of
CT and DXA measurements to provide robust biological readouts
to compare the association between different estimates of visceral
adiposity. Then, the subjects were recruited from a well-defined
population, which represented a single ethnic group under well-
defined conditions and healthy medical criteria. This study also
has several limitations, due to exploratory nature and the use of a
single cohort study with a small number of subjects and the results
are confined to this specific cohort. Therefore, further studies are
needed to determine the predictive role of the highlighted
metabolic signature clustering of cardiometabolic risk factors and
subsequent incidence of cardiovascular diseases. Since the
metabolic signatures encompass features related to glucose/insulin
metabolism, future studies should investigate closely the relation-
ships between metabolism, visceral adiposity and glucose tolerance
classes. Moreover, there is compelling evidence that relationships
between abdominal fat distribution and insulin and non-insulin-
mediated glucose uptake in females are dependent on endogenous
androgens [62], whilst the global adiposity and thickness of
intraperitoneal and mesenteric adipose tissue depots have been
found increased in women with polycystic ovary syndrome [63]. It
will be therefore key in future studies to comprehensively integrate
endocrinopathy with metabonomics and other physiological
parameters.
Conclusions
The integration of visceral fat estimates with metabolic profiles
of blood and urine described a distinct amino acid, diacyl and
ether phospholipid phenotype associated with higher visceral fat in
a healthy obese women cohort. Metabolite importance and
robustness in predicting visceral fat adiposity as assessed by
Random forest analysis highlighted 7 most robust markers,
including tyrosine, glutamine, PC-O 44:6, PC-O 44:4, PC-O
42:4, PC-O 40:4, and PC-O 40:3.Moreover, the inflammatory
intermediate profile appears of lower relevance for clinical
assessment of visceral fat due to greater inter-days and between-
subject variations. Considering the recent studies regarding at
metabolic processes associated with different body fat distributions,
it becomes imperative that the following studies comprehensively
report anthropometric, endocrine, clinical and medical details of
the cohort, in addition to race/ethnic and age variability. This will
allow a stronger link to unravel metabolic susceptibilities to
metabolic syndrome and cardiovascular health. Such reports will
enable proper comparison of metabolic findings and follow-up in
larger populations. In future, systemic metabonomic visceral
adiposity biomarkers might also be extended to distinguish its
mesenteric, epicardial and peripheric deposition subtypes which
may link even more specifically to cardiometabolic status of
patients with disorders or at risk of diseases.
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square analysis of Log10 value of ratio 1 with CT and
DEXA body composition parameters. OPLS model was
generated with 1 predictive and 2 orthogonal components
(R2X = 0.60, R2Y = 0.96, Q2Y = 0.90).
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analysis of CT, DEXA body composition and clinical
parameters. First two pprincipal components explained 29 and
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Figure S4 Loadings plot from orthogonal partial least
square analysis of Log10 value of ratio 1 with CT and
DEXA body composition parameters. OPLS model was
generated with 1 predictive and 2 orthogonal components
(R2X = 0.45, R2Y = 0.92, Q2Y = 0.75).
(TIF)
Figure S5 Linear regression between glucose response
to OGTT and visceral adiposity.
(TIF)
Figure S6 Statistical reconstruction of 1H NMR blood
plasma profiles using random forest analysis to identify
metabolic patterns associated with visceral adiposity (as
identified with squared boxes). GPCs = glycerophospholi-
pids, PUFAs = polyunsaturated fatty acids, UFAs = unsaturated
fatty acids.
(TIF)
Figure S7 Scheme summarizing metabolic differences
in the arachidonic and linoleic acid metabolic pathway
across the four groups of visceral adiposity (Q1, Q2, Q3,
and Q4). Bar plots describing metabolite variations in the study
population stratified in four quartiles according to visceral fat
adiposity (intraperitoneal fat). Statistical significance is reported in
Table S2. Key: Qi: data for population quartile i according to
intraperitoneal/abdominal fat ratio. 12-HETE, 12-hydroxy-eico-
satetraenoic acid; 15-HETE, 12-hydroxy-eicosatetraenoic acid; 9-
HODE, 9-Hydroxy-10,12-octadecadienoic acid; AA, arachidonic
acid.
(TIF)
Figure S8 Statistically significant Spearman correlation
map between visceral fat parameters CT scan, DXA
data and main clinical parameters (95% confidence
interval). HOMA-IR is negatively correlated with PC-O 42:4,
PC-O 44:4, and PC-O 44:6 lipid species, and positively with blood
triglycerides, cGT, and age. ALAT/ASAT ratio showed positive
correlations with AA and EPA, PC 34:4, PC 30:0 and LPC 24:0
lipid species, but also fasting blood insulin, cGT and triglycerides,
waist circumference and waist to hip ratio. Blue denotes negative
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no correlation.
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